⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822042 | 0.90 | — | — | |
| SCHEMBL5974883 | 0.88 | — | — | |
| SCHEMBL5747306 | 0.60 | — | — | |
| SCHEMBL19952780 | 0.60 | — | — | |
| SCHEMBL343499 | 0.60 | — | — | |
| SCHEMBL9153126 | 0.60 | — | — | |
| SCHEMBL291795 | 0.60 | — | — | |
| SCHEMBL1304516 | 0.60 | — | — | |
| SCHEMBL9433880 | 0.59 | — | — | |
| SCHEMBL127435 | 0.52 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194486-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-07-10 | — | — | US | claimed |
| US-20110224274-A1 | New Therapeutic Agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-09-15 | — | — | US | claimed |
| EP-2315749-A2 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2011-05-04 | — | — | EP | claimed |
| WO-2009156735-A2 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-30 | — | — | WO | claimed |
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20190155162-A1 | PATTERN-FORMING METHOD AND COMPOSITION FOR RESIST PATTERN-REFINEMENT | JSR CORPORATION (JP) | 2019-05-23 | — | — | US | disclosed |
| US-10005753-B2 | Methods for producing beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20170166545-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20160355478-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160291462-A1 | PATTERN-FORMING METHOD AND COMPOSITION FOR RESIST PATTERN-REFINEMENT | JSR CORPORATION (JP) | 2016-10-06 | — | — | US | disclosed |
| US-9358222-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-07 | — | — | US | disclosed |
| US-6482834-B2 | ANTIPROLIFERATION AGENTS; ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-19 | — | — | US | disclosed |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-09-20 | — | — | US | disclosed |
| EP-1133481-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6245760-B1 | ANTICANCER AGENTS; ANTIINFLAMMATORYA GENTS; SKIN DISORDERS | AVENTIS PHARMACEUTICALS PRODUCTS, INC | 2001-06-12 | — | — | US | disclosed |
| EP-1001946-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000031049-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-1001946-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1998054157-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |